SEQUENTIAL DETERMINATIONS OF URINARY CYTOLOGY AND PLASMA AND URINARY LYMPHOKINES IN THE MANAGEMENT OF RENAL ALLOGRAFT RECIPIENTS
Authors:
Open Access
- 1 February 1989
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 47 (2) , 218-222
Abstract
Urine cytology, plasma (P), and urinary (U) interleukin-2 (IL-2)* and IL-2 receptor (IL-2R) levels were evaluated as immunological monitoring techniques in 65 renal allograft recipients. Normal individuals showed normal urine cytology, IL-2(U) = 0, IL-2(P) = 0.4 +/- 0.1 ng/ml (mean +/- SEM) and IL-2R(P) = 318 +/- 26 U/ml. Stable transplants also showed normal urine cytology, no IL-2(U), IL-2(P) = 0.8 +/- 0.2 ng/ml, and IL-2R(P) = 326 +/- 29 U/ml. Rejection episodes (n = 21) were accompanied by cytologic changes, including lymphocyturia, exfoliation of immature tubular cells, platelet aggregates, and fibrin deposits. The corresponding lymphokine changes were IL-2(U) = 39.6 +/- 1.4 ng/ml, IL-2(P) = 79 +/- 21 ng/ml, and IL-2R = 1884 +/- 202 U/ml, all markedly increased. Successful treatment was associated with return of all parameters to normal; treatment failure was associated with continued abnormalities. Fourteen rejections unresponsive to Solumedrol (500 mg x 5 days) required OKT3 rescue (5 mg x 14 days). In the 11 that were reversed, onset of OKT3 therapy was characterized by markedly increased exfoliation of necrotic cellular debris, lymphocytes, and collecting duct cells. Interestingly, serum creatinine increases of 57.2 +/- 18.9% (range 25-90%) over pre-OKT3 levels were noted. Maximal changes occurred 48-72 hr after the first dose, followed by gradual return to normal. Rejections unresponsive to OKT3 (n = 3) showed no cytologic changes from the pretreatment mean creatinine increase of 13.2 +/- 2.7% (range 9-15%), and maximum change occurred 24 hr after the first dose. Rejections responsive to Solumedrol only (n = 4) showed gradual improvement of all parameters. Rejections treated with Solumedrol following failed OKT3 prophylaxis (n = 3) did not reverse and continued to show rejection associated cytologic changes and abnormal creatinines. Patients experiencing CsA toxicity (n = 12) showed mild creatinine elevations, normal or negative IL-2(P) and IL-2R(P) levels, and no IL-2(U). They showed distinctive cytologic changes consisting of swollen convoluted tubular cells with nuclear pyknosis and cytoplasmic vacuoles. Pretransplant IL-2(P) levels of patients who subsequently rejected were elevated, with 19/21 patients with preoperative IL-2 levels greater than 15 ng/ml having subsequent rejections. In contrast, pretransplant creatinine, urine cytology, and IL-2(U) levels showed no correlation to subsequent clinical course.(ABSTRACT TRUNCATED AT 400 WORDS)Keywords
This publication has 8 references indexed in Scilit:
- INTERLEUKIN 2, INTERFERON, AND LYMPHOTOXIN IN RENAL TRANSPLANT RECIPIENTS1 Pressented at the 6th Annual Meeting of the American Society of Transplant Physicians, May 1987, Chicago, ILTransplantation, 1988
- The Utility of Cytodiagnostic Urinalysis for Monitoring Renal Allograft InjuryAmerican Journal of Nephrology, 1988
- INTERLEUKIN-2 RECEPTOR LEVELS ARE INCREASED IN BLOOD OF HEART-TRANSPLANT PATIENTS DURING INFECTIONS1987
- BINDING OF ANTIHUMAN GLOBULIN BY EXFOLIATED RENAL TUBULAR CELLS FOLLOWING KIDNEY TRANSPLANTATIONTransplantation, 1985
- Induction of Interleukin 2 Messenger RNA Inhibited by Cyclosporin AScience, 1984
- Stimulation of lymphokine release from T lymphoblasts. Requirement for mRNA synthesis and inhibition by cyclosporin A.Journal of Experimental Medicine, 1984
- Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription.Proceedings of the National Academy of Sciences, 1984
- Lymphocyturia: an Important Diagnostic and Prognostic Marker in Renal Allograft RejectionAmerican Journal of Nephrology, 1982